^
    5ms
    PInNACLe: Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=60, Completed, Australasian Leukaemia and Lymphoma Group | Unknown status --> Completed | N=100 --> 60
    Trial completion • Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Tasigna (nilotinib) • ViraferonPeg (peginterferon-α-2b)
    over1year
    Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: May 2023 --> May 2026
    Trial completion date
    |
    temozolomide • ViraferonPeg (peginterferon-α-2b)
    over1year
    EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov)
    P3, N=1334, Completed, Children's Oncology Group | Unknown status --> Completed
    Trial completion • Surgery
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • ViraferonPeg (peginterferon-α-2b)
    2years
    Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. (PubMed, Cancers (Basel))
    Later, pegylated IFN-α2a (Pegasys) and pegylated IFN-α2b (PegIntron) were introduced, which have since been reported to be better tolerated due to reduced toxicity...Within the hematological malignancies, rIFN-α2 has been used off-label for decades in patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPNs)-i.e., essential thrombocythemia, polycythemia vera, and myelofibrosis-and in recent years rIFN-α2 has been revived with the marketing of ropeginterferon-α2b (Besremi) for the treatment of polycythemia vera patients...Another rIFN formulation-recombinant interferon-β (rIFN-β)-has been used for decades in the treatment of multiple sclerosis but has never been studied as a potential agent to be used in patients with MPNs, although several studies and reviews have repeatedly described rIFN-β as an effective anticancer agent as well. In this paper, we describe the rationales and perspectives for launching studies on the safety and efficacy of rIFN-β in patients with MPNs.
    Journal
    |
    IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
    |
    Pegasys (pegylated interferon α -2a) • Besremi (ropeginterferon alfa-2b-njft) • ViraferonPeg (peginterferon-α-2b)
    over3years
    Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Study was closed to accrual due to lack of drug supply.
    Clinical • Trial termination
    |
    IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
    |
    Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)
    4years
    Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=40 --> 18 | Trial completion date: Jul 2023 --> Sep 2020 | Trial primary completion date: Apr 2022 --> Sep 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • IFNA1 (Interferon Alpha 1)
    |
    Actimmune (interferon gamma-1 b) • ViraferonPeg (peginterferon-α-2b)
    almost5years
    Peginterferon and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=12, Completed, Inge Marie Svane | Active, not recruiting --> Completed
    Clinical • Trial completion • Combination therapy
    |
    IL2 (Interleukin 2)
    |
    fludarabine IV • Proleukin (aldesleukin) • ViraferonPeg (peginterferon-α-2b) • cyclophosphamide intravenous